Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» ICER
ICER
Drug price hikes without new evidence upped spending by $1.2B, ICER says
Drug price hikes without new evidence upped spending by $1.2B, ICER says
MedCity News
drug pricing
ICER
Flag link:
Price for Gilead's COVID-19 drug should shrink if cheap steroid widely used, ICER says
Price for Gilead's COVID-19 drug should shrink if cheap steroid widely used, ICER says
BioPharma Dive
Gilead Sciences
remdesivir
ICER
drug pricing
steriod
Flag link:
Vertex's cystic fibrosis drugs work, but they're too expensive, ICER finds
Vertex's cystic fibrosis drugs work, but they're too expensive, ICER finds
Endpoints
Vertex Pharmaceuticals
drug pricing
cystic fibrosis
ICER
Flag link:
What can Linux and Mozilla teach ICER about how to do drug value assessments?
What can Linux and Mozilla teach ICER about how to do drug value assessments?
Pharmaforum
ICER
drug value assessments
Flag link:
New sickle cell drugs priced too high, ICER says
New sickle cell drugs priced too high, ICER says
BioPharma Dive
sickle cell disease
drug pricing
ICER
Novartis
Global Blood Therapeutics
RWE
Adakveo
Oxbryta
Flag link:
In final report, ICER appears to have a change of heart on new acute migraine therapies
In final report, ICER appears to have a change of heart on new acute migraine therapies
Endpoints
ICER
migraines
Biohaven
Allergan
ubrogepant
rimegepant
Eli Lilly
Lasmiditan
Flag link:
Trifecta of sickle cell disease therapies extend life expectancy, but are not cost-effective — ICER
Trifecta of sickle cell disease therapies extend life expectancy, but are not cost-effective — ICER
Endpoints
ICER
sickle cell disease
Novartis
Adakveo
Global Blood Therapeutics
Oxbryta
Emmaus Life Sciences
Endari
Flag link:
ICER Warns of ‘Short-Term Budget Challenges’ with Novo’s Rybelsus
ICER Warns of ‘Short-Term Budget Challenges’ with Novo’s Rybelsus
Xtalks
Novo Nordisk
Rybelsus
oral semaglutide
diabetes
ICER
drug pricing
Flag link:
ICER says ‘marginal’ benefits for AbbVie’s new RA drug
ICER says ‘marginal’ benefits for AbbVie’s new RA drug
Pharmaforum
ICER
AbbVie
Rinvoq
rheumatoid arthritis
biosimilars
Flag link:
ICER draws new gene therapy pricing framework
ICER draws new gene therapy pricing framework
Biopharma Dive
ICER
gene therapy
Flag link:
U.S. Sponsors Of Health Insurance Lack Evidence-Based Transparency In Formulary Decisions
U.S. Sponsors Of Health Insurance Lack Evidence-Based Transparency In Formulary Decisions
Forbes
insurers
transparency
formulary
ICER
Flag link:
J&J's Xarelto, Amarin's Vascepa are cost-effective, not budget friendly — ICER
J&J's Xarelto, Amarin's Vascepa are cost-effective, not budget friendly — ICER
Endpoints
ICER
drug pricing
JNJ
Xarelto
Amarin
Vascepa
Flag link:
ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class
ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class
Fierce Pharma
ICER
AbbVie
Rinvoq
rheumatoid arthritis
JAK inhibitors
Flag link:
Humira, Rituxan top list of U.S. drugs with biggest price increases -report
Humira, Rituxan top list of U.S. drugs with biggest price increases -report
Yahoo/Reuters
ICER
drug pricing
AbbVie
Humira
Roche
Rituxan
Flag link:
ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach
ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach
Fierce Pharma
ICER
JAK inhibitors
rheumatoid arthritis
AbbVie
Rinvoq
Pfizer
Xeljanz
Incyte
olumiant
Flag link:
ICER dings Novo's new oral diabetes drug
ICER dings Novo's new oral diabetes drug
Biopharma Dive
Novo Nordisk
diabetes
ICER
oral semaglutide
Eli Lilly
Boehringer Ingelheim
Jardiance
Ozempic
Flag link:
New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER
New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER
Endpoints
peanut allergy
Aimmune Therapeutics
DBV Technologies
ICER
AR101
Viaskin Peanut
Flag link:
Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato
Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato
Fierce Pharma
Novartis
Mayzent
JNJ
Spravato
ICER
Flag link:
UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER
UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER
Endpoints
Duchenne Muscular Dystrophy
ICER
Sarepta Therapeutics
Exondys 51
Flag link:
ICER seeks to make drug price research more accessible
ICER seeks to make drug price research more accessible
Biopharma Dive
ICER
drug pricing
Flag link:
Pages
1
2
3
next ›
last »